Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1

Chad R. Heatwole, Katy J. Eichinger, Deborah I Friedman, James E. Hilbert, Carlayne E. Jackson, Eric L. Logigian, William B. Martens, Michael P. McDermott, Shree K. Pandya, Christine Quinn, Alexis M. Smirnow, Charles A. Thornton, Richard T. Moxley

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objective: To evaluate the safety and tolerability of recombinant human insulin-like growth factor 1 (rhIGF-1) complexed with IGF binding protein 3 (rhIGF-1/ rhIGFBP-3) in patients with myotonic dystrophy type 1 (DM1). Design: Open-label dose-escalation clinical trial. Setting: University medical center. Participants: Fifteen moderately affected ambulatory participants with genetically proven myotonic dystrophy type 1. Intervention: Participants received escalating dosages of subcutaneous rhIGF-1/rhIGFBP-3 for 24 weeks followed by a 16-week washout period. Main Outcome Measures: Serial assessments of safety, muscle mass, muscle function, and metabolic state were performed. The primary outcome variable was the ability of participants to complete 24 weeks receiving rhIGF-1/ rhIGFBP-3 treatment. Results: All participants tolerated rhIGF-1/rhIGFBP-3. There were no significant changes in muscle strength or functional outcomes measures. Lean body muscle mass measured by dual-energy x-ray absorptiometry increased by 1.95 kg (P<.001) after treatment. Participants also experienced a mean reduction in triglyceride levels of 47 mg/dL(P=.002), a mean increase in HDL levels of 5.0 mg/dL (P=.03), a mean reduction in hemoglobin A1c levels of 0.15% (P=.03), and a mean increase in testosterone level (in men) of 203 ng/dL (P=.002) while taking rhIGF-1/ rhIGFBP-3. Mild reactions at the injection site occurred (9 participants), as did mild transient hypoglycemia (3), light headedness (2), and transient papilledema (1). Conclusions: Treatment with rhIGF-1/rhIGFBP-3 was generally well tolerated in patients with myotonic dystrophy type 1. Treatment with rhIGF-1/rhIGFBP-3 was associated with increased lean body mass and improvement in metabolism but not increased muscle strength or function. Larger randomized controlled trials would be needed to further evaluate the efficacy and safety of this medication in patients with neuromuscular disease. Trial Registration: clinicaltrials.gov Identifier: NCT00233519.

Original languageEnglish (US)
Pages (from-to)37-44
Number of pages8
JournalArchives of Neurology
Volume68
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Myotonic Dystrophy
Somatomedins
Muscle Strength
Safety
Muscles
Outcome Assessment (Health Care)
Neuromuscular Diseases
Papilledema
Insulin-Like Growth Factor Binding Protein 3
human IGFBP3 protein
Protein
Insulin
Dizziness
Therapeutics
Hypoglycemia
Testosterone
Hemoglobins
Triglycerides
Randomized Controlled Trials
X-Rays

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. / Heatwole, Chad R.; Eichinger, Katy J.; Friedman, Deborah I; Hilbert, James E.; Jackson, Carlayne E.; Logigian, Eric L.; Martens, William B.; McDermott, Michael P.; Pandya, Shree K.; Quinn, Christine; Smirnow, Alexis M.; Thornton, Charles A.; Moxley, Richard T.

In: Archives of Neurology, Vol. 68, No. 1, 01.2011, p. 37-44.

Research output: Contribution to journalArticle

Heatwole, CR, Eichinger, KJ, Friedman, DI, Hilbert, JE, Jackson, CE, Logigian, EL, Martens, WB, McDermott, MP, Pandya, SK, Quinn, C, Smirnow, AM, Thornton, CA & Moxley, RT 2011, 'Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1', Archives of Neurology, vol. 68, no. 1, pp. 37-44. https://doi.org/10.1001/archneurol.2010.227
Heatwole, Chad R. ; Eichinger, Katy J. ; Friedman, Deborah I ; Hilbert, James E. ; Jackson, Carlayne E. ; Logigian, Eric L. ; Martens, William B. ; McDermott, Michael P. ; Pandya, Shree K. ; Quinn, Christine ; Smirnow, Alexis M. ; Thornton, Charles A. ; Moxley, Richard T. / Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. In: Archives of Neurology. 2011 ; Vol. 68, No. 1. pp. 37-44.
@article{039ee63b72cf44bcbe81a10f5a0ca39c,
title = "Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1",
abstract = "Objective: To evaluate the safety and tolerability of recombinant human insulin-like growth factor 1 (rhIGF-1) complexed with IGF binding protein 3 (rhIGF-1/ rhIGFBP-3) in patients with myotonic dystrophy type 1 (DM1). Design: Open-label dose-escalation clinical trial. Setting: University medical center. Participants: Fifteen moderately affected ambulatory participants with genetically proven myotonic dystrophy type 1. Intervention: Participants received escalating dosages of subcutaneous rhIGF-1/rhIGFBP-3 for 24 weeks followed by a 16-week washout period. Main Outcome Measures: Serial assessments of safety, muscle mass, muscle function, and metabolic state were performed. The primary outcome variable was the ability of participants to complete 24 weeks receiving rhIGF-1/ rhIGFBP-3 treatment. Results: All participants tolerated rhIGF-1/rhIGFBP-3. There were no significant changes in muscle strength or functional outcomes measures. Lean body muscle mass measured by dual-energy x-ray absorptiometry increased by 1.95 kg (P<.001) after treatment. Participants also experienced a mean reduction in triglyceride levels of 47 mg/dL(P=.002), a mean increase in HDL levels of 5.0 mg/dL (P=.03), a mean reduction in hemoglobin A1c levels of 0.15{\%} (P=.03), and a mean increase in testosterone level (in men) of 203 ng/dL (P=.002) while taking rhIGF-1/ rhIGFBP-3. Mild reactions at the injection site occurred (9 participants), as did mild transient hypoglycemia (3), light headedness (2), and transient papilledema (1). Conclusions: Treatment with rhIGF-1/rhIGFBP-3 was generally well tolerated in patients with myotonic dystrophy type 1. Treatment with rhIGF-1/rhIGFBP-3 was associated with increased lean body mass and improvement in metabolism but not increased muscle strength or function. Larger randomized controlled trials would be needed to further evaluate the efficacy and safety of this medication in patients with neuromuscular disease. Trial Registration: clinicaltrials.gov Identifier: NCT00233519.",
author = "Heatwole, {Chad R.} and Eichinger, {Katy J.} and Friedman, {Deborah I} and Hilbert, {James E.} and Jackson, {Carlayne E.} and Logigian, {Eric L.} and Martens, {William B.} and McDermott, {Michael P.} and Pandya, {Shree K.} and Christine Quinn and Smirnow, {Alexis M.} and Thornton, {Charles A.} and Moxley, {Richard T.}",
year = "2011",
month = "1",
doi = "10.1001/archneurol.2010.227",
language = "English (US)",
volume = "68",
pages = "37--44",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1

AU - Heatwole, Chad R.

AU - Eichinger, Katy J.

AU - Friedman, Deborah I

AU - Hilbert, James E.

AU - Jackson, Carlayne E.

AU - Logigian, Eric L.

AU - Martens, William B.

AU - McDermott, Michael P.

AU - Pandya, Shree K.

AU - Quinn, Christine

AU - Smirnow, Alexis M.

AU - Thornton, Charles A.

AU - Moxley, Richard T.

PY - 2011/1

Y1 - 2011/1

N2 - Objective: To evaluate the safety and tolerability of recombinant human insulin-like growth factor 1 (rhIGF-1) complexed with IGF binding protein 3 (rhIGF-1/ rhIGFBP-3) in patients with myotonic dystrophy type 1 (DM1). Design: Open-label dose-escalation clinical trial. Setting: University medical center. Participants: Fifteen moderately affected ambulatory participants with genetically proven myotonic dystrophy type 1. Intervention: Participants received escalating dosages of subcutaneous rhIGF-1/rhIGFBP-3 for 24 weeks followed by a 16-week washout period. Main Outcome Measures: Serial assessments of safety, muscle mass, muscle function, and metabolic state were performed. The primary outcome variable was the ability of participants to complete 24 weeks receiving rhIGF-1/ rhIGFBP-3 treatment. Results: All participants tolerated rhIGF-1/rhIGFBP-3. There were no significant changes in muscle strength or functional outcomes measures. Lean body muscle mass measured by dual-energy x-ray absorptiometry increased by 1.95 kg (P<.001) after treatment. Participants also experienced a mean reduction in triglyceride levels of 47 mg/dL(P=.002), a mean increase in HDL levels of 5.0 mg/dL (P=.03), a mean reduction in hemoglobin A1c levels of 0.15% (P=.03), and a mean increase in testosterone level (in men) of 203 ng/dL (P=.002) while taking rhIGF-1/ rhIGFBP-3. Mild reactions at the injection site occurred (9 participants), as did mild transient hypoglycemia (3), light headedness (2), and transient papilledema (1). Conclusions: Treatment with rhIGF-1/rhIGFBP-3 was generally well tolerated in patients with myotonic dystrophy type 1. Treatment with rhIGF-1/rhIGFBP-3 was associated with increased lean body mass and improvement in metabolism but not increased muscle strength or function. Larger randomized controlled trials would be needed to further evaluate the efficacy and safety of this medication in patients with neuromuscular disease. Trial Registration: clinicaltrials.gov Identifier: NCT00233519.

AB - Objective: To evaluate the safety and tolerability of recombinant human insulin-like growth factor 1 (rhIGF-1) complexed with IGF binding protein 3 (rhIGF-1/ rhIGFBP-3) in patients with myotonic dystrophy type 1 (DM1). Design: Open-label dose-escalation clinical trial. Setting: University medical center. Participants: Fifteen moderately affected ambulatory participants with genetically proven myotonic dystrophy type 1. Intervention: Participants received escalating dosages of subcutaneous rhIGF-1/rhIGFBP-3 for 24 weeks followed by a 16-week washout period. Main Outcome Measures: Serial assessments of safety, muscle mass, muscle function, and metabolic state were performed. The primary outcome variable was the ability of participants to complete 24 weeks receiving rhIGF-1/ rhIGFBP-3 treatment. Results: All participants tolerated rhIGF-1/rhIGFBP-3. There were no significant changes in muscle strength or functional outcomes measures. Lean body muscle mass measured by dual-energy x-ray absorptiometry increased by 1.95 kg (P<.001) after treatment. Participants also experienced a mean reduction in triglyceride levels of 47 mg/dL(P=.002), a mean increase in HDL levels of 5.0 mg/dL (P=.03), a mean reduction in hemoglobin A1c levels of 0.15% (P=.03), and a mean increase in testosterone level (in men) of 203 ng/dL (P=.002) while taking rhIGF-1/ rhIGFBP-3. Mild reactions at the injection site occurred (9 participants), as did mild transient hypoglycemia (3), light headedness (2), and transient papilledema (1). Conclusions: Treatment with rhIGF-1/rhIGFBP-3 was generally well tolerated in patients with myotonic dystrophy type 1. Treatment with rhIGF-1/rhIGFBP-3 was associated with increased lean body mass and improvement in metabolism but not increased muscle strength or function. Larger randomized controlled trials would be needed to further evaluate the efficacy and safety of this medication in patients with neuromuscular disease. Trial Registration: clinicaltrials.gov Identifier: NCT00233519.

UR - http://www.scopus.com/inward/record.url?scp=78651312601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651312601&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2010.227

DO - 10.1001/archneurol.2010.227

M3 - Article

C2 - 20837825

AN - SCOPUS:78651312601

VL - 68

SP - 37

EP - 44

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 1

ER -